EHA 2025 – ELVN-001 enlivens investors
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
EHA 2025 – Incyte puts its foot on the CALR gas
INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
Backed by ASCO data Arcus guns for phase 3
Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
AbbVie's telisotuzumab conjugate take two
A phase 2/3 study might show whether teliso-A can do better than teliso-V.
Merck speeds its KRAS into the colorectal front line
The move follows promising but early data presented at ASCO.
ASCO 2025 movers – bispecifics to the rescue
PD-(L)1 x VEGF developments coinciding with ASCO overshadowed the conference proper.
Werner not good enough for Roche
Roche dumps another partnered asset.
ASCO 2025 – J&J challenges its own multiple myeloma T-cell engagers
Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.
ASCO 2025 – BioNTech shows promise in mesothelioma
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
